Clinical Trials Register

Trials with a EudraCT protocol (680)
Paediatric studies in scope of Art45 of the Paediatric Regulation (126)

680 result(s) found for: Cellular. Displaying page 34 of 34.

EudraCT Number: 2008-000583-16

Sponsor Protocol Number: 312041

Start Date*: 2009-03-13

Sponsor Name:Bayer Schering Pharma AG (BSP)

Full Title: Multi-center, randomized comparison study to eVALUatE outcomes and resource needs of imaging and treatment following Primovist-enhanced MRI of the liver in comparison to extracellular contrast medi...

Medical condition: Patients with history of colorectal cancer and known or suspected metachronous liver metastasis(es) scheduled to undergo contrast-enhanced tomographic imaging (i.e. CE-MRI or CE-CT) of the liver

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10052358	Colorectal cancer metastatic	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: AT (Completed) SE (Completed) NL (Completed) ES (Completed) IT (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2018-000813-19

Sponsor Protocol Number: EURE-CART-1

Start Date*: 2019-09-04

Sponsor Name:MolMed S.p.A.

Full Title: A Phase I-IIa trial to assess the safety and antitumor activity of autologous CD44v6 CAR T-cells in acute myeloid leukemia and multiple myeloma expressing CD44v6.

Medical condition: Acute myeloid leukemia and Multiple myeloma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004864	10028228	Multiple myeloma	LLT
	20.0	100000004864	10000886	Acute myeloid leukemia	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2018-003949-42

Sponsor Protocol Number: 208471

Start Date*: 2019-12-11

Sponsor Name:GlaxoSmithKline Research & Development Ltd

Full Title: A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or i...

Medical condition: Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2015-001786-10

Sponsor Protocol Number: EPI589-15-002

Start Date*: 2016-01-18

Sponsor Name:BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)

Full Title: A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson’s Disease Subjects

Medical condition: Parkinson’s disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029205 - Nervous system disorders	10061536	Parkinson's disease	PT
	20.0	10029205 - Nervous system disorders	10061536	Parkinson's disease	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2019-001283-30

Sponsor Protocol Number: SPK-3006-101

Start Date*: 2020-06-16

Sponsor Name:Spark Therapeutics

Full Title: Phase 1/2, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of SPK-3006 in adults with late-onset Pompe disease

Medical condition: Pompe Disease (also known as glycogen storage disease type II)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	10010331 - Congenital, familial and genetic disorders	10053185	Glycogen storage disease type II	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: FR (Prematurely Ended) DE (Trial now transitioned) NL (Ongoing) DK (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2021-003526-80

Sponsor Protocol Number: CLSG-PTCL-CHEPA

Start Date*: 2021-12-16

Sponsor Name:Kooperativní lymfomová skupina, z.s.

Full Title: A Phase II Open Label Study of Brentuximab Vedotin in combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas.

Medical condition: Peripheral T-cell lymphomas (PTCL)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004851	10002450	Angioimmunoblastic T-cell lymphomas	HLT
	20.0	100000004851	10001414	Adult T-cell lymphomas/leukaemias	HLT
	20.0	100000004851	10022704	Intestinal T-cell lymphomas	HLT
	20.0	100000004851	10034622	Peripheral T-cell lymphomas NEC	HLT
	21.0	100000004864	10002451	Angioimmunoblastic T-cell lymphoma NOS	LLT
	21.0	100000004864	10001415	Adult T-cell lymphoma/leukaemia NOS	LLT
	21.1	100000004864	10076434	Hepatosplenic gamma-delta T-cell lymphoma	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: CZ (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2017-000106-38

Sponsor Protocol Number: JCAR017-BCM-001

Start Date*: 2018-06-14

Sponsor Name:Celgene Corporation

Full Title: A Phase 2, Single-arm, Multi-cohort, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCEND WORLD)

Medical condition: Aggressive B-cell Non Hodgkin Lymphoma (B-NHL)

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.0	100000004864	10029593	Non-Hodgkin's lymphoma NOS	LLT
	20.0	10005329 - Blood and lymphatic system disorders	10025320	Lymphomas non-Hodgkin's B-cell	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) FR (Completed) FI (Completed) ES (Restarted) DE (Completed) AT (Completed) NL (Ongoing) GB (Temporarily Halted) IT (Completed)

Trial results: View results

EudraCT Number: 2020-005858-21

Sponsor Protocol Number: WWU190007

Start Date*: 2021-09-17

Sponsor Name:Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel

Full Title: PHASE III STUDY COMPARING TRABECTEDIN (T) VERSUS T PLUS tTF-NGR TO ENTRAP T INSIDE THE TUMOR IN PATIENTS WITH METASTATIC AND/OR REFRACTORY SOFT TISSUE SARCOMA (STS)

Medical condition: Patients (18-75 years) with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing 1st line therapy or with contraindications to anthracyclines (CD13 positivity:...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073135	Dedifferentiated liposarcoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024628	Liposarcomas malignant	HLT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024629	Liposarcoma metastatic	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024630	Liposarcoma non-metastatic	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024627	Liposarcoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024632	Liposarcoma recurrent	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024631	Liposarcoma NOS	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024633	Liposarcoma stage unspecified	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073136	Mixed-type liposarcoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073137	Myxoid liposarcoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073138	Pleomorphic liposarcoma	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073139	Round cell liposarcoma	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10077843	Myxoid liposarcoma metastatic	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016634	Fibrosarcomas malignant	HLT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016635	Fibrosarcoma metastatic	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016636	Fibrosarcoma non-metastatic	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016632	Fibrosarcoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016637	Fibrosarcoma NOS	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016638	Fibrosarcoma stage unspecified	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066948	Myxofibrosarcoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024190	Leiomyosarcomas	HLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041127	Small intestine leiomyosarcoma	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024191	Leiomyosarcoma metastatic	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024192	Leiomyosarcoma non-metastatic	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024189	Leiomyosarcoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024194	Leiomyosarcoma recurrent	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10046799	Uterine leiomyosarcoma	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057340	Testicular leiomyosarcoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10024193	Leiomyosarcoma NOS	LLT
	22.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10082419	Pleomorphic leiomyosarcoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10039023	Rhabdomyosarcomas	HLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10039022	Rhabdomyosarcoma	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10039027	Rhabdomyosarcoma recurrent	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10039024	Rhabdomyosarcoma NOS	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10039026	Rhabdomyosarcoma previously untreated	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10039025	Rhabdomyosarcoma previously treated	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065867	Alveolar rhabdomyosarcoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025224	Lymphangiosarcomas	HLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025223	Lymphangiosarcoma	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002477	Angiosarcoma metastatic	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057700	Angiosarcoma non-metastatic	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002476	Angiosarcoma	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002480	Angiosarcoma recurrent	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002478	Angiosarcoma nonmetastatic	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002479	Angiosarcoma NOS	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10018828	Haemangiosarcoma NOS	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025225	Lymphangiosarcoma NOS	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002481	Angiosarcoma stage unspecified	LLT
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10019407	Hemangiosarcoma	LLT
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10018827	Haemangiosarcoma	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10067388	Hepatic angiosarcoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10072813	Breast angiosarcoma	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10072814	Breast angiosarcoma metastatic	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10072891	Skin angiosarcoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10077861	Cholangiosarcoma	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10042864	Synovial sarcoma metastatic	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10042865	Synovial sarcoma non-metastatic	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10042863	Synovial sarcoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10042867	Synovial sarcoma recurrent	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10042866	Synovial sarcoma NOS	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10045515	Undifferentiated sarcoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) AT (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2011-001192-39

Sponsor Protocol Number: P11-1

Start Date*: 2012-01-26

Sponsor Name:Dendreon Corporation

Full Title: AN OPEN-LABEL STUDY OF SIPULEUCEL-T IN EUROPEAN MEN WITH METASTATIC, CASTRATE RESISTANT PROSTATE CANCER

Medical condition: metastatic castrate resistant prostate cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036909	Prostate cancer metastatic	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036910	Prostate cancer NOS	LLT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066489	Progression of prostate cancer	LLT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036916	Prostate cancer stage D	LLT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10062904	Hormone-refractory prostate cancer	PT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: AT (Completed) GB (Completed) NL (Completed)

Trial results: View results

EudraCT Number: 2010-020116-11

Sponsor Protocol Number: CAUY922A2206

Start Date*: 2010-11-22

Sponsor Name:Novartis Pharma Services AG

Full Title: A phase II, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in patients with advanced non-small-cell lung cancer who have received at least two lines of prior che...

Medical condition: patients with advanced non-small-cell lung cancer who have received at least two lines of prior chemotherapy

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066490	Progression of non-small cell lung cancer	LLT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2011-004672-11

Sponsor Protocol Number: SNOXA12C201

Start Date*: 2012-03-05

Sponsor Name:NOXXON Pharma AG

Full Title: A multi-centre, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficiacy of NOX-A12 in combination with a background therapy of bendamustine and rituximab (BR) in prev...

Medical condition: Relapsed chronic lymphocytic leukemia

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10008958	Chronic lymphocytic leukaemia	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) BE (Completed) IT (Completed) AT (Completed)

Trial results: View results

EudraCT Number: 2017-003081-27

Sponsor Protocol Number: EHVAT01/ANRSVRI05

Start Date*: 2018-02-19

Sponsor Name:Inserm-ANRS

Full Title: EHVA T01(European HIV Vaccine Alliance Therapeutic Trial 01)/ANRS VRI05: A Phase I/II randomised therapeutic HIV vaccine trial in individuals who started antiretrovirals during primary or chronic i...

Medical condition: Human Immunodeficiency Virus (HIV) infection

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	10021881 - Infections and infestations	10020161	HIV infection	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended) IT (Completed)

Trial results: View results

EudraCT Number: 2014-001354-42

Sponsor Protocol Number: IAMI-2014

Start Date*: 2014-12-16

Sponsor Name:Örebro University Hospital

Full Title: Influenza vaccination After Myocardial Infarction (IAMI trial). A multicenter, prospective, randomized controlled clinical trial based on national angiography and angioplasty registries

Medical condition: Myocardial infarction

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10007541 - Cardiac disorders	10028596	Myocardial infarction	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Completed) DK (Completed) LV (Completed) CZ (Completed) NO (Completed) GB (GB - no longer in EU/EEA)

Trial results: View results

EudraCT Number: 2011-004250-26

Sponsor Protocol Number: CO-338-010

Start Date*: 2012-02-02

Sponsor Name:Clovis Oncology Inc.

Full Title: A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Ovarian Cancer, or Other Solid Tumor

Medical condition: Patients with locally advanced or metastatic solid tumors including lymphoma and germline BRCA (gBRCA) ovarian cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.0	100000004864	10049280	Solid tumour	LLT
	19.0	100000004864	10033130	Ovarian cancer NOS	LLT
	19.0	100000004864	10025315	Lymphoma malignant	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Prematurely Ended) ES (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2007-005668-28

Sponsor Protocol Number: AGAL06207

Start Date*: 2008-07-29

Sponsor Name:Genzyme Europe BV

Full Title: A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (agalsidase beta) in Treatment-Naive Male Pediatric Patients with Fabry Disease Without Severe Symp...

Medical condition: Fabry disease

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10010331 - Congenital, familial and genetic disorders	10016016	Fabry's disease	PT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male

Trial protocol: GB (Completed) NL (Completed) PT (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2019-003686-17

Sponsor Protocol Number: WiNK

Start Date*: 2020-07-03

Sponsor Name:Glycostem Therapeutics BV

Full Title: A prospective Phase I/IIa, open-label, multicenter trial to evaluate the safety and efficacy of oNKord®, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation, in subjects with acute my...

Medical condition: acute myeloid leukaemia

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004864	10000886	Acute myeloid leukemia	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) DE (Completed) FR (Completed) NL (Completed)

Trial results: (No results available)

EudraCT Number: 2008-000252-28

Sponsor Protocol Number: SHCVOLT1

Start Date*: 2009-03-13

Sponsor Name:Cambridge University Hospitals NHS Foundation Trust

Full Title: A Multi-Centre Prospective Controlled Trial Comparing Calcineurin Inhibitor Monotherapy With Sirolimus Monotherapy in Hepatitis C Infected Patients with Hepatic Fibrosis Following Liver Transplanta...

Medical condition: Patients who have undergone liver transplantation and are infected with Hepatitis C virus.

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10052779	Transplant rejections	HLT
	9.1		10024970	Respiratory tract infections	HLGT
	9.1		10046577	Urinary tract infections	HLT
	9.1		10001032	Acute pyelonephritis	LLT
	9.1		10040072	Septicaemia	LLT
	9.1		10019972	Herpes viral infections	HLT
	9.1		10028440	Mycobacterial infectious disorders	HLGT
	9.1		10015107	Epstein-Barr viral infections	HLT
	9.1		10011831	Cytomegalovirus infection	LLT
	9.1		10019974	Herpes zoster	LLT
	9.1		10058872	Fungal sepsis	LLT
	9.1		10040808	Skin cancer	PT
	9.1		10051358	Post transplant lymphoproliferative disorder	LLT
	9.1		10043555	Thrombocytopenias	HLT
	9.1		10037561	Purpura thrombocytopenic	LLT
	9.1		10002034	Anaemia	PT
	9.1		10018932	Haemolytic uraemic syndrome	PT
	9.1		10024384	Leukopenia	PT
	9.1		10029355	Neutropenias	HLT
	9.1		10033661	Pancytopenia	PT
	9.1		10013505	Disturbance of liver function tests	LLT
	9.1		10002218	Anaphylaxis	LLT
	9.1		10002425	Angioedemas	HLT
	9.1		10015665	Exfoliative dermatitis	LLT
	9.1		10020764	Hypersensitivity vasculitis	LLT
	9.1		10021015	Hypokalaemia	PT
	9.1		10021058	Hypophosphataemia	PT
	9.1		10020603	Hypercholesterolaemia	PT
	9.1		10020635	Hyperglycaemia	PT
	9.1		10020869	Hypertriglyceridaemia	PT
	9.1		10043071	Tachycardia	PT
	9.1		10034474	Pericardial effusion	PT
	9.1		10048642	Lymphocele	PT
	9.1		10051055	Deep vein thrombosis	PT
	9.1		10037377	Pulmonary embolism	PT
	9.1		10025282	Lymphoedema	PT
	9.1		10035742	Pneumonitis	PT
	9.1		10035598	Pleural effusion	PT
	9.1		10015090	Epistaxis	PT
	9.1		10037394	Pulmonary haemorrhage	PT
	9.1		10000081	Abdominal pain	PT
	9.1		10012735	Diarrhoea	PT
	9.1		10042128	Stomatitis	PT
	9.1		10033645	Pancreatitis	PT
	9.1		10000496	Acne	PT
	9.1		10037844	Rash	PT
	9.1		10003239	Arthralgia	PT
	9.1		10031264	Osteonecrosis	PT
	9.1		10037032	Proteinuria	PT
	9.1		10029164	Nephrotic syndrome	PT
	9.1		10030124	Oedema peripheral	PT
	9.1		10021519	Impaired healing	PT
	9.1		10030095	Oedema	PT
	9.1		10037660	Pyrexia	PT
	9.1		10005630	Blood lactate dehydrogenase increased	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Prematurely Ended)

Trial results: View results

EudraCT Number: 2013-001747-31

Sponsor Protocol Number: CLCZ696D2301

Start Date*: 2013-09-24

Sponsor Name:Novartis Pharma Services AG

Full Title: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure pat...

Medical condition: Heart failure with preserved ejection fraction

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	100000004849	10069211	Diastolic heart failure	LLT
	20.0	100000004849	10019279	Heart failure	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SK (Completed) HU (Completed) AT (Completed) BG (Completed) DE (Prematurely Ended) ES (Completed) NO (Completed) GB (Completed) NL (Completed) CZ (Completed) IT (Completed) SE (Completed) BE (Completed) DK (Completed) GR (Completed) FI (Completed) HR (Completed) PL (Completed) SI (Completed)

Trial results: View results

EudraCT Number: 2016-000816-14

Sponsor Protocol Number: CO-338-043

Start Date*: 2016-11-24

Sponsor Name:Clovis Oncology, Inc.

Full Title: Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Medical condition: Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10038977	Retroperitoneal cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061328	Ovarian epithelial cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016180	Fallopian tube cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Ongoing) PL (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2017-000705-20

Sponsor Protocol Number: EsPhALL2017/COGAALL1631

Start Date*: 2017-12-11

Sponsor Name:Università degli Studi Milano Bicocca

Full Title: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

Medical condition: Philadelphia positive Acute Lumphoblastic Leukemia

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10022891 - Investigations	10034877	Philadelphia chromosome positive	PT
	21.0	100000004864	10000844	Acute lymphoblastic leukaemia	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: AT (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials for Cellular